TY - JOUR
KW - Adrenal Cortex Hormones/therapeutic use
KW - Aged
KW - Aged, 80 and over
KW - Bronchodilator Agents/adverse effects
KW - Delivery of Health Care
KW - Disease Progression
KW - England/epidemiology
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Muscarinic Antagonists/adverse effects
KW - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology
KW - Retrospective Studies
KW - Global Initiative for Chronic Obstructive Lung Disease
KW - chronic obstructive lung disease
KW - Database
KW - exacerbations
KW - healthcare costs
KW - Maintenance therapy
AU - L. Sansbury
AU - K. Rothnie
AU - C. Bains
AU - C. Compton
AU - G. Anley
AU - A. Ismaila
AD - Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, Durham, NC, USA.
Value and Evidence Outcomes, GlaxoSmithKline, Uxbridge, UK.
Real World Evidence and Epidemiology, GlaxoSmithKline, Uxbridge, UK.
Global Respiratory Franchise, GlaxoSmithKline, Brentford, UK.
Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA.
Department of Health Research Methods, McMaster University, Hamilton, ON, Canada.
AN - 34552325
BT - Int J Chron Obstruct Pulmon Dis
C2 - PMC8450675
DO - 10.2147/copd.s318969
DP - NLM
ET - 2021/09/24
LA - eng
N1 - 1178-2005
Sansbury, Leah B
Rothnie, Kieran J
Bains, Chanchal
Compton, Chris
Anley, Glenn
Ismaila, Afisi S
Orcid: 0000-0002-2876-8308
Journal Article
Int J Chron Obstruct Pulmon Dis. 2021 Sep 15;16:2591-2604. doi: 10.2147/COPD.S318969. eCollection 2021.
PY - 2021
SN - 1176-9106 (Print)1176-9106
SP - 2591
EP - 2604
T2 - Int J Chron Obstruct Pulmon Dis
TI - Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England
VL - 16
ER -